- Home
- BBTX vs AQST Comparison
BBTX vs AQST Comparison
Compare BBTX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$16.95
N/A
Current Price
$3.54
Company Overview
Basic Information| Metric | BBTX | AQST |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.2M | 529.4M |
| IPO Year | 2026 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BBTX | AQST |
|---|---|---|
| Price | $16.95 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | N/A | ★ 2.4M |
| Earning Date | 12-16-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.36 |
| Revenue Next Year | N/A | $38.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | N/A | $2.94 |
| 52 Week High | N/A | $6.74 |
Technical Indicators
Market Signals| Indicator | BBTX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.23 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $4.34 |
| Average True Range (ATR) | 0.00 | 0.22 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 15.76 |
Price Performance
Historical Comparison BBTX
AQST
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.